Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis

Science Translational Medicine

Volumn 10, Issue 468, 2018, Pages

  Zhu, Changyu ^a   Kim, KyeongJin ^a   Wang, Xiaobo ^a   Bartolome, Alberto ^a   Salomao, Marcela ^b   Dongiovanni, Paola ^c   Meroni, Marica ^c   Graham, Mark J ^d   Yates, Katherine P ^e   Diehl, Anna Mae ^f   Schwabe, Robert F ^a   Tabas, Ira ^a   Valenti, Luca ^c   Lavine, Joel E ^a   Pajvani, Utpal B ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d ISIS PHARMACEUTICALS   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; METHIONINE; NOTCH RECEPTOR; OSTEOPONTIN; SPP1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR SOX9;

ANIMAL; C57BL MOUSE; COMPLICATION; DIET; FEMALE; HEPATIC STELLATE CELL; HUMAN; LIVER CELL; LIVER CIRRHOSIS; MALE; METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOLOGY;

ANIMALS; CHOLINE; DIET; FEMALE; HEPATIC STELLATE CELLS; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; MALE; METHIONINE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OSTEOPONTIN; RECEPTORS, NOTCH; SOX9 TRANSCRIPTION FACTOR;

EID: 85056944365     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/SCITRANSLMED.AAT0344     Document Type: Article

References (76)

1. P. Hossain, B. Kawar, M. El Nahas, Obesity and diabetes in the developing world—A growing challenge. N. Engl. J. Med. 356, 213–215 (2007).
2. M. Lazo, J. M. Clark, The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin. Liver Dis. 28, 339–350 (2008).
3. C. L. Ogden, M. D. Carroll, C. D. Fryar, K. M. Flegal, Prevalence of obesity among adults and youth: United States, 2011-2014. NCHS data brief 28, 339–350 (2015).
4. Z. M. Younossi, M. Stepanova, M. Afendy, Y. Fang, Y. Younossi, H. Mir, M. Srishord, Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 9, 524–530.e1 (2011).
5. E. M. Brunt, Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 195–203 (2010).
6. S. Gawrieh, N. Chalasani, Pharmacotherapy for nonalcoholic fatty liver disease. Semin. Liver Dis. 35, 338–348 (2015).
7. D. Kim, W. R. Kim, H. J. Kim, T. M. Therneau, Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 57, 1357–1365 (2013).
8. P. S. Dulai, S. Singh, J. Patel, M. Soni, L. J. Prokop, Z. Younossi, G. Sebastiani, M. Ekstedt, H. Hagstrom, P. Nasr, P. Stal, V. W. Wong, S. Kechagias, R. Hultcrantz, R. Loomba, Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 65, 1557–1565 (2017).
9. P. Angulo, D. E. Kleiner, S. Dam-Larsen, L. A. Adams, E. S. Bjornsson, P. Charatcharoenwitthaya, P. R. Mills, J. C. Keach, H. D. Lafferty, A. Stahler, S. Haflidadottir, F. Bendtsen, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389–397.e10 (2015).
10. M. Ekstedt, H. Hagström, P. Nasr, M. Fredrikson, P. Stål, S. Kechagias, R. Hultcrantz, Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547–1554 (2015).
11. M. E. Fortini, D. Bilder, Endocytic regulation of Notch signaling. Hepatology 19, 323–328 (2009).
12. B. De Strooper, Nicastrin: Gatekeeper of the gamma-secretase complex. Cell 122, 318–320 (2005).
13. V. Bolós, J. Grego-Bessa, J. L. de la Pompa, Notch signaling in development and cancer. Endocr. Rev. 28, 339–363 (2007).
14. Y. Zong, B. Z. Stanger, Molecular mechanisms of liver and bile duct development. Wiley Interdiscip. Rev. Dev. Biol. 1, 643–655 (2012).
15. U. B. Pajvani, C. J. Shawber, V. T. Samuel, A. L. Birkenfeld, G. I. Shulman, J. Kitajewski, D. Accili, Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat. Med. 17, 961–967 (2011).
16. L. Valenti, R. M. Mendoza, R. Rametta, M. Maggioni, C. Kitajewski, C. J. Shawber, U. B. Pajvani, Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes 62, 4052–4062 (2013).
17. A. J. Sanyal, N. Chalasani, K. V. Kowdley, A. McCullough, A. M. Diehl, N. M. Bass, B. A. Neuschwander-Tetri, J. E. Lavine, J. Tonascia, A. Unalp, M. Van Natta, J. Clark, E. M. Brunt, D. E. Kleiner, J. H. Hoofnagle, P. R. Robuck; Nash CRN, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685 (2010).
18. N. P. Chalasani, A. J. Sanyal, K. V. Kowdley, P. R. Robuck, J. Hoofnagle, D. E. Kleiner, A. Unalp, J. Tonascia; NASH CRN Research Group, Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemp. Clin. Trials 30, 88–96 (2009).
19. X. Wang, Z. Zheng, J. M. Caviglia, K. E. Corey, T. M. Herfel, B. Cai, R. Masia, R. T. Chung, J. H. Lefkowitch, R. F. Schwabe, I. Tabas, Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab. 24, 848–862 (2016).
20. D. E. Kleiner, E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, M. Yeh, A. J. McCullough, A. J. Sanyal; Nonalcoholic Steatohepatitis Clinical Research Network, Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
21. S. Nowotschin, P. Xenopoulos, N. Schrode, A.-K. Hadjantonakis, A bright single-cell resolution live imaging reporter of Notch signaling in the mouse. BMC Dev. Biol. 13, 15 (2013).
22. L. Tu, T. C. Fang, D. Artis, O. Shestova, S. E. Pross, I. Maillard, W. S. Pear, Notch signaling is an important regulator of type 2 immunity. J. Exp. Med. 202, 1037–1042 (2005).
23. K. Yanger, Y. Zong, L. R. Maggs, S. N. Shapira, R. Maddipati, N. M. Aiello, S. N. Thung, R. G. Wells, L. E. Greenbaum, B. Z. Stanger, Robust cellular reprogramming occurs spontaneously during liver regeneration. Genes Dev. 27, 719–724 (2013).
24. X. Mu, R. Español-Suñer, I. Mederacke, S. Affò, R. Manco, C. Sempoux, F. P. Lemaigre, A. Adili, D. Yuan, A. Weber, K. Unger, M. Heikenwälder, I. A. Leclercq, R. F. Schwabe, Hepatocellular carcinoma originates from hepatocytes and not from the progenitor/biliary compartment. J. Clin. Invest. 125, 3891–3903 (2015).
25. K. Tabuchi, G. Chen, T. C. Südhof, J. Shen, Conditional forebrain inactivation of nicastrin causes progressive memory impairment and age-related neurodegeneration. J. Neurosci. 29, 7290–7301 (2009).
26. K. Kim, I. J. Goldberg, M. J. Graham, M. Sundaram, E. Bertaggia, S. X. Lee, L. Qiang, R. A. Haeusler, D. Metzger, P. Chambon, Z. Yao, H. N. Ginsberg, U. B. Pajvani, γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor. Cell Metab. 27, 816–827.e14 (2018).
27. Y. Chen, S. Zheng, D. Qi, S. Zheng, J. Guo, S. Zhang, Z. Weng, Inhibition of notch signaling by a γ-secretase inhibitor attenuates hepatic fibrosis in rats. PLOS ONE 7, e46512 (2012).
28. R. Bansal, J. van Baarlen, G. Storm, J. Prakash, The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Sci. Rep. 5, 18272 (2015).
29. F. He, F. C. Guo, Z. Li, H. C. Yu, P. F. Ma, J. L. Zhao, L. Feng, W. N. Li, X. W. Liu, H. Y. Qin, K. F. Dou, H. Han, Myeloid-specific disruption of recombination signal binding protein Jκ ameliorates hepatic fibrosis by attenuating inflammation through cylindromatosis in mice. Hepatology 61, 303–314 (2015).
30. L. Hebbard, J. George, Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35–44 (2011).
31. M. E. Rinella, R. M. Green, The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol. 40, 47–51 (2004).
32. C. M. Morell, R. Fiorotto, M. Meroni, A. Raizner, B. Torsello, M. Cadamuro, G. Spagnuolo, E. Kaffe, S. Sutti, E. Albano, M. Strazzabosco, Notch signaling and progenitor/ductular reaction in steatohepatitis. PLOS One 12, e0187384 (2017).
33. L. C. Murtaugh, B. Z. Stanger, K. M. Kwan, D. A. Melton, Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. U.S.A. 100, 14920–14925 (2003).
34. J. J. Pan, M. B. Fallon, Gender and racial differences in nonalcoholic fatty liver disease. World J. Hepatol. 6, 274–283 (2014).
35. M. V. Machado, A. M. Diehl, Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology 150, 1769–1777 (2016).
36. T. Hardy, F. Oakley, Q. M. Anstee, C. P. Day, Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annu. Rev. Pathol. 11, 451–496 (2016).
37. J. P. Iredale, Hepatic stellate cell behavior during resolution of liver injury. Semin. Liver Dis. 21, 427–436 (2001).
38. S. L. Friedman, Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver. Physiol. Rev. 88, 125–172 (2008).
39. D. Yimlamai, C. Christodoulou, G. G. Galli, K. Yanger, B. Pepe-Mooney, B. Gurung, K. Shrestha, P. Cahan, B. Z. Stanger, F. D. Camargo, Hippo pathway activity influences liver cell fate. Cell 157, 1324–1338 (2014).
40. X. Wang, A. Lopategi, X. Ge, Y. Lu, N. Kitamura, R. Urtasun, T. M. Leung, M. I. Fiel, N. Nieto, Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 63, 1805–1818 (2014).
41. M. V. Machado, G. A. Michelotti, T. A. Pereira, G. Xie, R. Premont, H. Cortez-Pinto, A. M. Diehl, Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease. J. Hepatol. 63, 962–970 (2015).
42. M. J. Williams, A. D. Clouston, S. J. Forbes, Links between hepatic fibrosis, ductular reaction, and progenitor cell expansion. Gastroenterology 146, 349–356 (2014).
43. M. M. Richardson, J. R. Jonsson, E. E. Powell, E. M. Brunt, B. A. Neuschwander-Tetri, P. S. Bhathal, J. B. Dixon, M. D. Weltman, H. Tilg, A. R. Moschen, D. M. Purdie, A. J. Demetris, A. D. Clouston, Progressive fibrosis in nonalcoholic steatohepatitis: Association with altered regeneration and a ductular reaction. Gastroenterology 133, 80–90 (2007).
44. I. Mederacke, C. C. Hsu, J. S. Troeger, P. Huebener, X. Mu, D. H. Dapito, J. P. Pradere, R. F. Schwabe, Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat. Commun. 4, 2823 (2013).
45. W. K. Syn, S. S. Choi, E. Liaskou, G. F. Karaca, K. M. Agboola, Y. H. Oo, Z. Mi, T. A. Pereira, M. Zdanowicz, P. Malladi, Y. Chen, C. Moylan, Y. Jung, S. D. Bhattacharya, V. Teaberry, A. Omenetti, M. F. Abdelmalek, C. D. Guy, D. H. Adams, P. C. Kuo, G. A. Michelotti, P. F. Whitington, A. M. Diehl, Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 53, 106–115 (2011).
46. R. Urtasun, A. Lopategi, J. George, T.-M. Leung, Y. Lu, X. Wang, X. Ge, M. I. Fiel, N. Nieto, Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin αVβ3 engagement and PI3K/pAkt/NFκB signaling. Hepatology 55, 594–608 (2012).
47. J. D. Coombes, M. Swiderska-Syn, L. Dollé, D. Reid, B. Eksteen, L. Claridge, M. A. Briones-Orta, S. Shetty, Y. H. Oo, A. Riva, S. Chokshi, S. Papa, Z. Mi, P. C. Kuo, R. Williams, A. Canbay, D. H. Adams, A. M. Diehl, L. A. van Grunsven, S. S. Choi, W. K. Syn, Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice. Gut 64, 1120–1131 (2015).
48. A. Sahai, P. Malladi, H. Melin-Aldana, R. M. Green, P. F. Whitington, Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 287, G264–G273 (2004).
49. Y. Zong, A. Panikkar, J. Xu, A. Antoniou, P. Raynaud, F. Lemaigre, B. Z. Stanger, Notch signaling controls liver development by regulating biliary differentiation. Development 136, 1727–1739 (2009).
50. Q. Shen, S. Christakos, The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J. Biol. Chem. 280, 40589–40598 (2005).
51. I. Espinoza, L. Miele, Notch inhibitors for cancer treatment. Pharmacol. Ther. 139, 95–110 (2013).
52. N. Takebe, D. Nguyen, S. X. Yang, Targeting notch signaling pathway in cancer: Clinical development advances and challenges. Pharmacol. Ther. 141, 140–149 (2014).
53. J. H. van Es, M. E. van Gijn, O. Riccio, M. van den Born, M. Vooijs, H. Begthel, M. Cozijnsen, S. Robine, D. J. Winton, F. Radtke, H. Clevers, Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435, 959–963 (2005).
54. D. P. Sparling, J. Yu, K. Kim, C. Zhu, S. Brachs, A. L. Birkenfeld, U. B. Pajvani, Adipocytespecific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity. Mol. Metab. 5, 113–121 (2016).
55. P. Bi, T. Shan, W. Liu, F. Yue, X. Yang, X. R. Liang, J. Wang, J. Li, N. Carlesso, X. Liu, S. Kuang, Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. Nat. Med. 20, 911–918 (2014).
56. D. Gaudet, D. Brisson, K. Tremblay, V. J. Alexander, W. Singleton, S. G. Hughes, R. S. Geary, B. F. Baker, M. J. Graham, R. M. Crooke, J. L. Witztum, Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371, 2200–2206 (2014).
57. M. J. Graham, R. G. Lee, T. A. Bell III, W. Fu, A. E. Mullick, V. J. Alexander, W. Singleton, N. Viney, R. Geary, J. Su, B. F. Baker, J. Burkey, S. T. Crooke, R. M. Crooke, Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112, 1479–1490 (2013).
58. D. Gaudet, V. J. Alexander, B. F. Baker, D. Brisson, K. Tremblay, W. Singleton, R. S. Geary, S. G. Hughes, N. J. Viney, M. J. Graham, R. M. Crooke, J. L. Witztum, J. D. Brunzell, J. J. Kastelein, Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 373, 438–447 (2015).
59. R. S. Geary, D. Norris, R. Yu, C. F. Bennett, Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
60. A. Suzuki, A. M. Diehl, Nonalcoholic Steatohepatitis. Annu. Rev. Med. 68, 85–98 (2017).
61. M. E. Rinella, Nonalcoholic fatty liver disease: A systematic review. JAMA 313, 2263–2273 (2015).
62. H. Cuervo, C. M. Nielsen, D. A. Simonetto, L. Ferrell, V. H. Shah, R. A. Wang, Endothelial notch signaling is essential to prevent hepatic vascular malformations in mice. Hepatology 64, 1302–1316 (2016).
63. A. Wittrup, J. Lieberman, Knocking down disease: A progress report on siRNA therapeutics. Nat. Rev. Genet. 16, 543–552 (2015).
64. C. Lorenzer, M. Dirin, A. M. Winkler, V. Baumann, J. Winkler, Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 203, 1–15 (2015).
65. D. Dehaini, R. H. Fang, L. Zhang, Biomimetic strategies for targeted nanoparticle delivery. Bioeng. Transl. Med. 1, 30–46 (2016).
66. S. Jörs, P. Jeliazkova, M. Ringelhan, J. Thalhammer, S. Dürl, J. Ferrer, M. Sander, M. Heikenwalder, R. M. Schmid, J. T. Siveke, F. Geisler, Lineage fate of ductular reactions in liver injury and carcinogenesis. J. Clin. Invest. 125, 2445–2457 (2015).
67. R. M. Mancina, P. Dongiovanni, S. Petta, P. Pingitore, M. Meroni, R. Rametta, J. Borén, T. Montalcini, A. Pujia, O. Wiklund, G. Hindy, R. Spagnuolo, B. M. Motta, R. M. Pipitone, A. Craxì, S. Fargion, V. Nobili, P. Käkelä, V. Kärjä, V. Männistö, J. Pihlajamaki, D. F. Reilly, J. Castro-Perez, J. Kozlitina, L. Valenti, S. Romeo, The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150, 1219–1230.e6 (2016).
68. C. Postic, M. A. Magnuson, DNA excision in liver by an albumin-Cre transgene occurs progressively with age. Genesis 26, 149–150 (2000).
69. U. B. Pajvani, L. Qiang, T. Kangsamaksin, J. Kitajewski, H. N. Ginsberg, D. Accili, Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat. Med. 19, 1055–1060 (2013).
70. C. M. Miller, M. Tanowitz, A. J. Donner, T. P. Prakash, E. E. Swayze, E. N. Harris, P. P. Seth, Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver. Nucleic Acid Ther. 28, 119–127 (2018).
71. L. Lisowski, A. P. Dane, K. Chu, Y. Zhang, S. C. Cunningham, E. M. Wilson, S. Nygaard, M. Grompe, I. E. Alexander, M. A. Kay, Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 506, 382–386 (2014).
72. K. Kim, L. Qiang, M. S. Hayden, D. P. Sparling, N. H. Purcell, U. B. Pajvani, mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. Nat. Commun. 7, 10255 (2016).
73. J. Font-Burgada, S. Shalapour, S. Ramaswamy, B. Hsueh, D. Rossell, A. Umemura, K. Taniguchi, H. Nakagawa, M. A. Valasek, L. Ye, J. L. Kopp, M. Sander, H. Carter, K. Deisseroth, I. M. Verma, M. Karin, Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell 162, 766–779 (2015).
74. I. Mederacke, D. H. Dapito, S. Affò, H. Uchinami, R. F. Schwabe, High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. Nat. Protoc. 10, 305–315 (2015).
75. J. Folch, M. Lees, G. H. Sloane Stanley, A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497–509 (1957).
76. J. P. Pradere, J. Kluwe, S. De Minicis, J. J. Jiao, G. Y. Gwak, D. H. Dapito, M. K. Jang, N. D. Guenther, I. Mederacke, R. Friedman, A. C. Dragomir, C. Aloman, R. F. Schwabe, Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology 58, 1461–1473 (2013).